

# Journal of Visualized Experiments

## A murine model of central venous stenosis: aortocaval fistula with an outflow stenosis --Manuscript Draft--

<b>Article Type:</b>	Methods Article - JoVE Produced Video
<b>Manuscript Number:</b>	JoVE59540R1
<b>Full Title:</b>	A murine model of central venous stenosis: aortocaval fistula with an outflow stenosis
<b>Keywords:</b>	Vascular biology, anatomy, physiology, surgery, aorta, inferior vena cava, arteriovenous fistula, aortocaval fistula, central vein stenosis, mouse, ligation, animal model
<b>Corresponding Author:</b>	Alan Dardik, M.D., Ph.D. Yale University School of Medicine New Haven, CT UNITED STATES
<b>Corresponding Author's Institution:</b>	Yale University School of Medicine
<b>Corresponding Author E-Mail:</b>	alan.dardik@yale.edu
<b>Order of Authors:</b>	Toshihiko Isaji, M.D., Ph.D. Shun Ono Takuya Hashimoto Kota Yamamoto Ryosuke Taniguchi Haidi Hu Tun Wang Jun Koizumi Toshiya Nishibe Katsuyuki Hoshina Alan Dardik
<b>Additional Information:</b>	
<b>Question</b>	<b>Response</b>
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the <b>city, state/province, and country</b> where this article will be <b>filmed</b> . Please do not use abbreviations.	New Haven, CT

**TITLE:**

Murine Model of Central Venous Stenosis using Aortocaval Fistula with an Outflow Stenosis

**AUTHORS AND AFFILIATIONS:**

Toshihiko Isaji<sup>1,2,3</sup>, Shun Ono<sup>1,2,4,5</sup>, Takuya Hashimoto<sup>1,2,3</sup>, Kota Yamamoto<sup>1,2,3</sup>, Ryosuke Taniguchi<sup>1,2,3</sup>, Haidi Hu<sup>1,2</sup>, Tun Wang<sup>1,2</sup>, Jun Koizumi<sup>4</sup>, Toshiya Nishibe<sup>5</sup>, Katsuyuki Hoshina<sup>3</sup>, Alan Dardik<sup>1,2,6</sup>

<sup>1</sup>Department of Surgery, Yale University, CT, USA

<sup>2</sup>Vascular Biology and Therapeutics Program, Yale University, CT, USA

<sup>3</sup>Department of Vascular Surgery, University of Tokyo, Tokyo, Japan

<sup>4</sup>Department of Diagnostic Radiology, Tokai University School of Medicine, Isehara, Japan

<sup>5</sup>Department of Cardiovascular Surgery, Tokyo Medical Univeristy, Tokyo, Japan

<sup>6</sup>Department of Vascular Surgery, VA Connecticut Healthcare Systems, CT, USA

**Corresponding Author:**

Alan Dardik

alan.dardik@yale.edu

Tel: (203)-737-2082

**Email Addresses of Co-authors:**

Toshihiko Isaji (isacci1976@gmail.com)

Shun Ono (shun.ono@yale.edu)

Takuya Hashimoto (takuyanni@gmail.com)

Kota Yamamoto (kmaysyamamo@gmail.com)

Ryosuke Taniguchi (ryosuke.taniguchi@yale.edu)

Haidi Hu (hdhu@mail.cmu.edu.cn)

Tun Wang (wangtun0423@163.com)

Jun Koizumi (jkoizumi@is.icc.u-tokai.ac.jp)

Toshiya Nishibe (toshiyanishibe@yahoo.co.jp)

Katsuyuki Hoshina (traruba@gmail.com)

**KEYWORDS:**

Vascular biology, anatomy, physiology, surgery, aorta, inferior vena cava, arteriovenous fistula, aortocaval fistula, central vein stenosis, mouse, ligation, animal model

**SUMMARY:**

An aortocaval fistula was created by puncturing the murine infra-renal aorta through both walls into the inferior vena cava and was followed by creation of a stenosis in its outflow via partial ligation of the inferior vena cava. This reproducible model can be used to study central venous stenosis.

**ABSTRACT:**

Central venous stenosis is an important entity contributing to arteriovenous fistula (AVF) failure.

A murine AVF model was modified to create a partial ligation of the inferior vena cava (IVC) in the outflow of the fistula, mimicking central venous stenosis. Technical aspects of this model are introduced. The aorta and IVC are exposed, following an abdominal incision. The infra-renal aorta and IVC are dissected for proximal clamping, and the distal aorta is exposed for puncture. The IVC at the midpoint between the left renal vein and the aortic bifurcation is carefully dissected to place an 8-0 suture beneath the IVC. After clamping the aorta and IVC, an AVF is created by puncturing the infra-renal aorta through both walls into the IVC with a 25 G needle, followed by ligating a 22 G intra-venous (IV) catheter and IVC together. The catheter is then removed, creating a reproducible venous stenosis without occlusion. The aorta and IVC are unclamped after confirming primary hemostasis. This novel model of central vein stenosis is easy to perform, reproducible, and will facilitate studies on AVF failure.

## **INTRODUCTION:**

Arteriovenous fistulae (AVF) are the most common accesses for hemodialysis, with superior patency and reduced infection compared to other accesses such as grafts or central venous catheters. However, up to 60% of AVF fail to mature<sup>1-3</sup>; a recent systematic review reported that primary patency rates at 1 year were only 60%<sup>4</sup>. Stenosis along the venous outflow predominantly causes failure of AVF maturation<sup>5,6</sup>. There are certain characteristic locations prone to stenosis proximal to the fistula: the juxtaanastomotic swing segment for the radiocephalic fistula, the cephalic arch region for the brachiocephalic fistula and the central vein for the fistula with previously placed ipsilateral subclavian or internal jugular vein catheters<sup>7,8</sup>.

Central venous stenosis is often asymptomatic in patients without an AVF, but can cause ipsilateral extremity edema by venous hypertension as well as failure of fistula maturation when challenged by fistula flow<sup>9</sup>. The pathophysiology of central venous stenosis is most likely related to inflammation and the activated coagulation cascade after device placement. Furthermore, constant movement of the catheter tip as well as increased flow from the fistula can alter shear stress, resulting in platelet deposition and venous wall thickening<sup>10</sup>. To understand the basic mechanisms underlying AVF failure caused by central venous stenosis, an animal model mimicking central venous stenosis with an AVF is required.

We have established a murine aortocaval fistula model that is easy to perform and master and recapitulates the clinical course of human AVF.<sup>11</sup> We applied the concepts and technique of several previously established murine models to create a novel murine AVF model with venous stenosis. We introduce a murine aortocaval fistula model with an IVC stenosis in the outflow fistula that can be used for the study of central venous stenosis.

## **PROTOCOL:**

All experiments were performed with approval from the Yale University Institutional Animal Care and Use Committee (IACUC).

### **1. Anesthesia and pre-operative procedures**

1.1. Sterilize all surgical instruments and materials by autoclaving. Turn on the thermal support

device to be certain it is warm (40–42 °C).

1.2. Place a 9–11-week old C57BL/6 mouse into an acrylic induction chamber and anesthetize it with vaporized 2.5% isoflurane and 0.8 L/min oxygen. Anesthesia induction takes about 3 min.

1.3. Remove the mouse from the chamber. Confirm a deep plane of anesthesia by a toe pinch. Place the mouse in supine position on the surgical area and deliver 2.5% isoflurane using silicone mask. Provide buprenorphine at 0.1 mg/kg analgesic and apply ophthalmic ointment to the eyes.

1.4. Remove fur from the ventral side of the neck to the lower abdomen using a hair remover.

1.5. Cleanse and disinfect the surgical site by using a two-step scrub with 10% povidone-iodine and 70% isopropanol. Apply a surgical drape.

## **2. Operative procedures**

### **2.1. Exposure of the clamp and puncture sites**

2.1.1. Prepare sterile instruments and wear sterile gloves to maintain sterility throughout the surgery.

2.1.2. Make a skin-deep midline abdominal incision with a scalpel from the level of the lower liver edge to just above the pubis. Cut through the musculature with scissors to open the abdominal cavity.

2.1.3. Insert a retractor into the abdomen and pull out the bowels to the right side. Keep them moist by wrapping in a saline-soaked gauze. Retrieve the bladder and the seminal vesicles (in male mice) and pull them out to the caudal side. Dissect the mesentery between the rectum and retroperitoneum with a micro-needle holder to obtain a full view of the aorta and IVC.

2.1.4. Dissect the infra-renal aorta and IVC en bloc from the lateral and dorsal surrounding retroperitoneal tissues with a micro-needle holder to cross-clamp them together.

2.1.5. Dissect the surrounding tissues to expose the aortic puncture site at approximately three-quarters of the distance from the left renal vein to the aortic bifurcation.

### **2.2. IVC dissection**

2.2.1. Dissect between the infra-renal IVC and aorta immediately distal to the left renal vein. Extend the dissection distally to the halfway between the left renal vein and the aortic bifurcation, so that the infra-renal IVC, both upstream and downstream to the stenosis, can be observed postoperatively.

NOTE: Blunt dissection between the IVC and aorta should be performed from immediately distal

to the left renal vein where the connective tissue between the IVC and the aorta is relatively loose.

2.2.2. Make a window to separate the IVC from the aorta at that level and dissect the IVC from the surrounding tissue. Place an 8-0 polyamide monofilament suture firstly beneath the IVC and aorta (**Figure 1A**), then position the suture beneath only the IVC (**Figure 1B**) by pulling the suture end through the window.

NOTE: Since the IVC is fragile, dissecting along the aortic adventitia is useful to make a window to prevent the IVC as well as small IVC or aortic branches from being damaged. If bleeding occurs, it is likely to be uncontrollable. If the IVC has distinct side branches, place an 8-0 suture distally to the branches.

### **2.3. AVF creation**

2.3.1. Bend a 25 G needle to a 45–60° angle at a point ~4 mm from the needle tip.

2.3.2. Clamp the infra-renal aorta and IVC by applying a microsurgical clip.

2.3.3. Rotate the aorta medially and caudally by grasping the connective tissue surrounding the bifurcation to expose the puncture site of the aorta stretched it slightly to the ventral side.

2.3.4. Holding the aorta in a suitable position, puncture through the aorta into the IVC using the prepared 25 G needle (**Figure 1C**).

2.3.5. Release the aorta and cover the puncture site with the surrounding tissue pulling up from the left side of the aorta. Take out the needle and press the puncture site gently using a cotton-tipped swab for hemostasis.

### **2.4. Creation of the IVC stenosis**

2.4.1. Place a tip of a 22 G IV catheter (see the **Table of Materials**) onto the IVC longitudinally. Ligate the IV catheter and IVC together with an 8-0 suture (**Figure 1D**), and then remove the IV catheter.

2.4.2. Confirm primary hemostasis (**Figure 1E**) and then unclamp the aorta and IVC. Cover the puncture site 1 min more to ensure hemostasis.

NOTE: Do not clamp for too long so as to avoid IVC thrombosis distal to the stenosis.

2.4.3. Return organs to their original positions and close the abdomen with 6-0 sutures.

### **3. Post-operative procedures**

3.1. After closure of the abdominal wound, discontinue isoflurane inhalation. Put the mouse into an individual bedding-free cage and place the cage on a thermal support device to prevent hypothermia.

NOTE: The mouse is observed until they achieve and maintain sternal recumbency. Apply post-operative care including analgesia and wound care in accordance with recommendations of the local IACUC. For analgesia we use buprenorphine at 0.1 mg/kg intramuscularly every 12 h for 24 h following the surgical procedures.

3.2. Confirm the AVF patency postoperatively by using Doppler ultrasound (see the **Table of Materials**). In addition, measure other vessel and flow characteristics as required.

#### **REPRESENTATIVE RESULTS:**

Male mice underwent the operation mentioned above to create both an AVF and an IVC stenosis. Control mice underwent only laparotomy and dissection of the tissues surrounding the IVC, e.g., a sham procedure, or only creation of an IVC stenosis without simultaneous creation of an AVF. The IVC was observed with Doppler ultrasound on day 7 after the surgical procedure (**Figure 2**). The fistula and stenosis areas of the IVC were easily detected in the longitudinal view (**Figure 2C,E**). The IVC between the fistula and the stenosis was dilated in mice having an AVF with the stenosis. The ultrasound waveforms were examined in the IVC at the point of the stenosis (**Figure 2D,F**). In mice bearing a stenosis alone, without an AVF, the stenosis segment showed a venous waveform with more spectral broadening than sham-operated mice but without much pulsatility. However, in mice having an AVF as well as a stenosis, the stenosis segment showed a pulsatile waveform in addition to spectral broadening. The time-averaged maximum velocity of the flow at the stenosis in mice having an AVF with stenosis was significantly higher than mice having stenosis alone (**Table 1**).

The Doppler ultrasound B mode was used in transverse views to assess the IVC on day seven after surgery (**Table 1**). The mean IVC diameter at the stenosis in mice having stenosis alone was similar to the mice having an AVF as well as the stenosis (**Table 1**). The percent stenosis of the IVC was calculated according to the NASCET method<sup>12</sup>. Using either the upstream segment or the downstream segment as the reference, the percent stenosis was significantly greater in mice having an AVF in addition to the stenosis (**Table 1**).

#### **FIGURE AND TABLE LEGENDS:**

**Figure 1. Operative photos of murine AVF model with venous stenosis.** (A) Place an 8-0 suture beneath the IVC (blue arrowheads) and aorta (red arrowheads) halfway between the left renal vein (yellow arrowheads) and the aortic bifurcation, distally to any large IVC branches if present. (B) Place the suture beneath the IVC only. (C) After proximal clamping, puncture the aorta through both walls and into the IVC. (D) Tie a tip of a 22 G IV catheter and the IVC together with the placed suture. (E) Remove the catheter and unclamp. Arterial blood flow through IVC stenosis can be observed.

**Figure 2. Ultrasound findings on day 7 after the surgical procedure.** Top: representative images of mice with a sham procedure. (A) B-mode image shows IVC in the longitudinal view. The left side is the cranial side. (B) Waveform of the infrarenal IVC. Middle: representative images of mice with a stenosis alone. (C) B-mode image shows IVC including the stenosis (yellow asterisk) in the longitudinal view. The left side is the cranial side. (D) Waveform in the area of the stenosis. Bottom: Representative images of mice having AVF with stenosis. (E) B-mode image shows IVC including fistula (white asterisk) and stenosis. The left side is the cranial side. (F) Waveform in the area of the stenosis. White scale bar represents 1 mm. Yellow scale bar represents 100 ms.

**Table 1. Ultrasound measurement at the IVC stenosis area of each group.** Ultrasound derived measurements at the IVC stenosis area of mice having stenosis alone and mice having AVF with stenosis on day 7 after surgery. %stenosis (upstream) =  $(1 - [\text{diameter at stenosis} / \text{diameter at upstream reference segment}]) \times 100\%$ . %stenosis (downstream) =  $(1 - [\text{diameter at stenosis} / \text{diameter at downstream reference segment}]) \times 100\%$ . %dilation =  $(\text{diameter on postoperative day 7} / \text{preoperative diameter at the same segment}) \times 100\%$ . *P* values are based on Student's *t*-tests, *n* = 4–6.

## DISCUSSION:

The murine AVF model has been used to study the basic mechanisms and molecular events leading to AVF maturation<sup>13,14</sup>. In this study, we modified an established murine AVF model to create a novel murine aortocaval fistula model with an IVC stenosis in the outflow tract of the fistula. Our ligation model is similar to several previously described murine models that use vascular ligation. A murine model of deep vein thrombosis was created using partial IVC ligation with a 30 G needle spacer<sup>15</sup>; we used a larger 22 G IV catheter spacer to create a smaller stenosis and thereby avoid thrombotic occlusion. A murine model of partial carotid artery ligation was used to induce disturbed flow, leading to atherosclerosis<sup>16</sup>; our model similarly used a partial venous ligation and accordingly demonstrated disturbed flow in the IVC at the area of the partial ligation.

Mechanisms underlying AVF maturation failure caused by fistula venous stenosis have been studied. Hemodynamic changes including disturbed frequencies of shear stress were shown to be important factors<sup>17,18</sup>. A computational fluid dynamics simulation showed disturbed flow at the venous stenosis<sup>19</sup>, although animal models of AVF with venous stenosis have not been previously reported. This modified murine aortocaval fistula model can be used to study an AVF with central venous stenosis. The IVC diameter at the stenosis has less variation and more consistency in this model; partial IVC ligation using an IV catheter increases the reproducibility of this model. Clinical symptoms and signs of central vein stenosis often develop only after fistula creation in the ipsilateral extremity<sup>9</sup>. In this model, mice having a partial IVC stenosis (<50%) had normal flow and were asymptomatic, whereas addition of an AVF increased the degree of stenosis to a degree that could cause symptoms (>50%) (**Figure 2, Table 1**). These results mimic the phenotype of central vein stenosis; increased venous flow due to the presence of the fistula can unveil the existence of asymptomatic central vein stenosis, causing venous hypertension and failure of fistula maturation.

There are some critical steps and points to improve the success rate and consistency of the procedure. If the IVC has distinct side branches, an 8-0 suture is placed distally (caudally) to the branches (**Figure 1**). In the original murine AVF model, side branches of IVC are typically ignored because the higher vascular resistance of the branches keeps the fistula flow from entering the branches. However, if the IVC stenosis is created proximally to distinct side branches in this model, the fistula flow may escape into the branches due to vascular resistance by the newly placed suture. To avoid massive bleeding, the IVC dissection is started immediately inferiorly to the left renal vein and is extended further inferiorly to the point where the IVC is to be ligated. This step is the most critical part of this surgery; bleeding from damaged IVC or branches is likely to be uncontrollable. Furthermore, to avoid touching the IVC when placing the suture around it, and potentially tearing it, the 8-0 suture is initially placed around both the IVC and the aorta, and then repositioned beneath only the IVC. Lastly, the knot of the 8-0 suture is placed on the side of the IVC, not directly anteriorly, to prevent any artifact that could affect the postoperative ultrasound examination.

A potential limitation of this study is that the IVC stenosis in this model is created by external mechanical compression; adventitial inflammation caused by the suture and IVC dissection could potentially affect venous remodeling at the stenosis area. In addition, the fistula in this model is made between aorta and IVC so that all the fistula flow is directed into the IVC stenosis, whereas the fistula created in the human upper extremity often allows collateral veins to develop, keeping the stenosis asymptomatic. Physical signs of central venous stenosis such as distal edema and collateral formation are not shown in this model.

In summary, we introduce a protocol for a novel murine aortocaval fistula model with an IVC outflow stenosis that is easy to perform and reproducible. We expect that this model will be useful to study hemodynamic changes by a central venous stenosis that could affect AVF maturation.

#### **ACKNOWLEDGMENTS:**

This work was supported by US National Institute of Health (NIH) Grant R01-HL128406; the United States Department of Veterans Affairs Biomedical Laboratory Research and Development Program Merit Review Award I01-BX002336; as well as with the resources and the use of facilities at the VA Connecticut Healthcare System, West Haven, CT.

#### **DISCLOSURES:**

The authors have nothing to disclose.

#### **REFERENCES:**

- 1 Dember, L. M. et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. *JAMA*. **299** (18), 2164-2171, (2008).
- 2 Dixon, B. S. Why don't fistulas mature? *Kidney International*. **70** (8), 1413-1422, (2006).
- 3 Wilmlink, T., Hollingworth, L., Powers, S., Allen, C., Dasgupta, I. Natural History of Common Autologous Arteriovenous Fistulae: Consequences for Planning of Dialysis. *European Journal of Vascular and Endovascular Surgery*. **51** (1), 134-140, (2016).



309 4 Al-Jaishi, A. A. et al. Patency rates of the arteriovenous fistula for hemodialysis: a  
310 systematic review and meta-analysis. *American Journal of Kidney Diseases*. **63** (3), 464-  
311 478, (2014).

312 5 Rocco, M. V., Bleyer, A. J., Burkart, J. M. Utilization of inpatient and outpatient resources  
313 for the management of hemodialysis access complications. *American Journal of Kidney  
314 Diseases*. **28** (2), 250-256, (1996).

315 6 Roy-Chaudhury, P., Sukhatme, V. P., Cheung, A. K. Hemodialysis vascular access  
316 dysfunction: a cellular and molecular viewpoint. *Journal of the American Society of  
317 Nephrology*. **17** (4), 1112-1127, (2006).

318 7 Quencer, K. B., Arici, M. Arteriovenous Fistulas and Their Characteristic Sites of Stenosis.  
319 *AJR: American Journal of Roentgenology*. **205** (4), 726-734, (2015).

320 8 Kian, K., Asif, A. Cephalic arch stenosis. *Semin Dial*. **21** (1), 78-82, (2008).

321 9 Agarwal, A. K. Central vein stenosis. *American Journal of Kidney Diseases*. **61** (6), 1001-  
322 1015, (2013).

323 10 Glanz, S. et al. Axillary and subclavian vein stenosis: percutaneous angioplasty. *Radiology*.  
324 **168** (2), 371-373, (1988).

325 11 Yamamoto, K. et al. The mouse aortocaval fistula recapitulates human arteriovenous  
326 fistula maturation. *American Journal of Physiology: Heart and Circulatory Physiology*. **305**  
327 (12), H1718-1725, (2013).

328 12 North American Symptomatic Carotid Endarterectomy Trial. Methods, patient  
329 characteristics, and progress. *Stroke*. **22** (6), 711-720, (1991).

330 13 Kuwahara, G. et al. CD44 Promotes Inflammation and Extracellular Matrix Production  
331 During Arteriovenous Fistula Maturation. *Arteriosclerosis, Thrombosis, and Vascular  
332 Biology*. **37** (6), 1147-1156, (2017).

333 14 Protack, C. D. et al. Eph-B4 regulates adaptive venous remodeling to improve  
334 arteriovenous fistula patency. *Scientific Reports*. **7** (1), 15386, (2017).

335 15 Payne, H., Brill, A. Stenosis of the Inferior Vena Cava: A Murine Model of Deep Vein  
336 Thrombosis. *J Vis Exp*. 10.3791/56697 (130), (2017).

337 16 Nam, D. et al. Partial carotid ligation is a model of acutely induced disturbed flow, leading  
338 to rapid endothelial dysfunction and atherosclerosis. *American Journal of Physiology:  
339 Heart and Circulatory Physiology*. **297** (4), H1535-1543, (2009).

340 17 Ene-lordache, B., Remuzzi, A. Disturbed flow in radial-cephalic arteriovenous fistulae for  
341 haemodialysis: low and oscillating shear stress locates the sites of stenosis. *Nephrology,  
342 Dialysis, Transplantation*. **27** (1), 358-368, (2012).


343 18 Yamamoto, K. et al. Disturbed shear stress reduces Klf2 expression in arterial-venous  
344 fistulae in vivo. *Physiological reports*. **3**, (2015).

345 19 Remuzzi, A., Ene-lordache, B. Novel paradigms for dialysis vascular access: upstream  
346 hemodynamics and vascular remodeling in dialysis access stenosis. *Clinical Journal of the  
347 American Society of Nephrology*. **8** (12), 2186-2193, (2013).


348

Figure 1


A.




B.



C.



D.



E.





Figure 2



Stenosis	Yes	Yes	
<u>AVF</u>	<u>No</u>	<u>Yes</u>	<u>P value</u>
Time-averaged maximum velocity (mm/s)	180	878	0.0023
Stenosis diameter (mm)	0.62 ± 0.01	0.63 ± 0.01	0.3558
% stenosis (upsteam)	43%	66%	0.0159
% stenosis (downsteam)	42%	56%	0.0006

Name of Material / Equipment	Company	Catalog Number	Comments/Description
20-60 Mhz scan head	VisualSonics Inc.	RMV-704	
8-0 Sterile Micro Suture, 6mm (140 μ), 3/8 Circle, TAP Point Needle	AROSuture	T06A08N14-13	polyamide monofilament sutures
Induction Chamber, 2 Liter 3.75"W x 9.00"D x 3.75"H	VetEquip	941444	
Isoflo, Isoflurane liquid	Zoetis	26675-46-7	
Mice, C57BL/6J	The Jackson Laboratory	664	
Pet Bed Microwave Heating Pad	Snuggle Safe	6250	
PrecisionGlide Needle 25G	BD	305122	
Surflo I.V. Catheter 22G	Terumo	SR-OX2225CA	0.85mm outer diameter
Vascular clamp	Roboz Surgical Instrument	RS-5424	
Vevo770 High Resolution Imaging System	VisualSonics Inc.	770	





1 Alewife Center #200  
Cambridge, MA 02140  
tel. 617.945.9051  
www.jove.com

## ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

*A murine model of central venous stenosis: aorticaval fistula with an outflow stenosis*

Author(s):

*Toshihiko Isaji, Shun Ono, Takuya Hashimoto, Kota Yamamoto, Ryosuke Taniguchi, Haruki Hu, Tun Wang, Jun Koizumi, Toshiya Nishibe, Katsuyuki Hoshino, Alan Dardik*

Item 1 (check one box): The Author elects to have the Materials be made available (as described at

http://www.jove.com/author) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

### ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: "**Agreement**" means this Article and Video License Agreement; "**Article**" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "**Author**" means the author who is a signatory to this Agreement; "**Collective Work**" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "**CRC License**" means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; "**Derivative Work**" means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; "**Institution**" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "**JoVE**" means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; "**Materials**" means the Article and / or the Video; "**Parties**" means the Author and JoVE; "**Video**" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.



## ARTICLE AND VIDEO LICENSE AGREEMENT

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have

## ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's

expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to me one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

### CORRESPONDING AUTHOR:

Name:

Alan Dardic MD PhD

Department:

Surgery

Institution:

Yale University

Article Title:

A murine model of central venous stenosis

Signature:



Date:

12/10/2018

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email [submissions@jove.com](mailto:submissions@jove.com) or call +1.617.945.9051



Thank you very much for the comments and suggestions. We appreciate the time spent by the Reviewers. Each of the questions is answered below and addressed in the Redline version of the manuscript. The paper is much improved; thank you again!

---

You will find Editorial comments and Peer-Review comments listed below. Please read this entire email before making edits to your manuscript.

NOTE: Please include a line-by-line response to each of the editorial and reviewer comments in the form of a letter along with the resubmission.

#### Editorial Comments:

- Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammatical errors.

Thank you. We confirm that there are no spelling or grammatical errors in the manuscript.

- Text Overlap: Significant portions of the manuscript show significant overlap with previously published work. Please re-write Lines 46-49, 90-92, 106-111, 143-157 using ALL original text to avoid this overlap.

Thank you for pointing this out. We have rewritten these parts using original text.

- Protocol Detail: Please note that your protocol will be used to generate the script for the video, and must contain everything that you would like shown in the video. Please add more specific details (e.g. button clicks for software actions, numerical values for settings, etc) to your protocol steps.

- 1) Please include an ethics statement before your numbered protocol steps indicating that the protocol follows the animal care guidelines of your institution.

- 2) 1.1: Mention sex if it matters.

- 3) 1.5: Mention povidone % and isopropanol %.

- 4) 2.1.2: How deep is the initial incision? Skin-deep? Or through the musculature?

- 5) 2.1.3: Mention tools used for dissection.

- 6) 2.1.4: Describe the dissection in a bit more detail.

Thank you for these questions.

- 1) We included the statement that all experiments are performed with approval from the Yale University Institutional Animal Care and Use Committee.
- 2) Both male and female mice could be used for this experiment.
- 3) We mention these concentrations.
- 4) We mention that the initial incision is skin-deep.
- 5) A micro-needle holder is used for dissection.
- 6) We described the detail of the infra-renal aorta IVC dissection.

· Discussion: JoVE articles are focused on the methods and the protocol, thus the discussion should be similarly focused. Please ensure that the discussion covers the following in detail and in paragraph form (3-6 paragraphs): 1) modifications and troubleshooting, 2) limitations of the technique, 3) significance with respect to existing methods, 4) future applications and 5) critical steps within the protocol.

Thank you for this instruction. We now address all these points in the discussion.

· Figures:

- 1) Fig 2: Please provide scale references on the images.

Scale references are provided in Fig 2.

· Tables:

- 1) Table 1: Mention statistical test used. Mention sample sizes.

Student's t-test was used and sample size were 4 to 6. We mention this in the table legend.

· References:

- 1) Please make sure that your references comply with JoVE instructions for authors. Citation formatting should appear as follows: (For 6 authors or less list all authors. For more than 6 authors, list only the first author then et al.): [Lastname, F.I., LastName, F.I., LastName, F.I. Article Title. Source. Volume (Issue), FirstPage – LastPage, (YEAR).]
- 2) Please spell out journal/source name.

We followed these instructions by downloading the JoVE Endnote styling from JoVE

website.

· Commercial Language: JoVE is unable to publish manuscripts containing commercial sounding language, including trademark or registered trademark symbols (TM/R) and the mention of company brand names before an instrument or reagent. Examples of commercial sounding language in your manuscript are Surflo® 22G; Terumo, (Vevo770 High 183 Resolution Imaging System

1) Please use MS Word's find function (Ctrl+F), to locate and replace all commercial sounding language in your manuscript with generic names that are not company-specific. All commercial products should be sufficiently referenced in the table of materials/reagents. You may use the generic term followed by "(see table of materials)" to draw the readers' attention to specific commercial names.

Thank you for this point. We followed these instructions.

· Table of Materials: Please revise the table of the essential supplies, reagents, and equipment. The table should include the name, company, and catalog number of all relevant materials/software in separate columns in an xls/xlsx file. Please include items such as surgical tools, ultrasound imager, animals, drugs used etc.

Thank you for this point. We followed this instruction and revised the table of materials.

· If your figures and tables are original and not published previously or you have already obtained figure permissions, please ignore this comment. If you are re-using figures from a previous publication, you must obtain explicit permission to re-use the figure from the previous publisher (this can be in the form of a letter from an editor or a link to the editorial policies that allows you to re-publish the figure). Please upload the text of the re-print permission (may be copied and pasted from an email/website) as a Word document to the Editorial Manager site in the "Supplemental files (as requested by JoVE)" section. Please also cite the figure appropriately in the figure legend, i.e. "This figure has been modified from [citation]."

The figure is original.

Comments from Peer-Reviewers:

Reviewer #1:

This is a very interesting and meaningful method article. The writing is excellent. However, I found some minor issues. It's best to polish it up before publication.

Minor Points:

1. It may be better to use centigrade or both;

We changed degrees from Fahrenheit to Celsius.

2. It might be better to describe the specific time of anesthesia induction;

We now describe this.

3. Is there any recycling equipment for anesthesia gas?

We do not use any recycling equipment for anesthesia gas.

4. In Figure 2, it is better to add a normal control (without any operation).

We added panels of the sham group as a normal control and mentioned this in the representative results section.

5. Please add some material/equipment information (acrylic induction chamber; thermal support device).

Thank you for this comment. We added information about the acrylic induction chamber and thermal support device in Table of Materials.

Reviewer #2:

Manuscript Summary:

This manuscript describes a new model of AVF and venous stenosis. It is well written and illustrated. This model is appropriate to study what happens to AVF in the presence of a venous stenosis, as one might see with a dialysis fistula in the arm and then a more central venous stenosis.

Major Concerns:

1. What type of suture did the authors use to place around the IVC? We have found that a non-reactive prolene suture will produce less surrounding inflammation than a silk suture. Can the authors provide this information?

Thank you for raising this interesting point. We use polyamide monofilament sutures, which produces less surrounding inflammation than silk sutures. We now address this in the Protocol section.

2. Why do the authors put the suture around both the artery and vein initially, rather than just going around the IVC?

Thank you for this question. The reason is that it is much safer. The IVC can easily be damaged if a needle holder goes around the IVC through the window between the IVC and aorta; we thus avoid touching the IVC when putting the suture around it. We now address this in the Discussion section.

3. Why do the authors use such a large spacer?

The reason we use a large spacer is to avoid creating a venous thrombosis. A spacer that is smaller than 22G can cause postsurgical thrombosis in the IVC distal to the stenosis; in fact, Payne et al.<sup>1</sup> used a 30G spacer to create a model of deep vein thrombosis. On the other hand, we created this model to create a stenosis without creating a thrombus, e.g. maintain venous flow.

4. Finally, can the authors clarify if they ligate all draining side branches, or just a few of them?

Thank you for this important question. We do not ligate any draining side branches. As mentioned in the discussion section, the IVC stenosis is created distally to distinct side branches to keep the fistula flow from entering branches. Side branches above the IVC stenosis do not affect the fistula flow as vascular resistance of the side branches is much higher than in the proximal IVC.

#### Minor Concerns:

1. For Figure 2, the authors should number the parts of their images and then refer to these numbers in their legend.

Thank you for this point. We followed this suggestion.

- 1 Payne, H. & Brill, A. Stenosis of the Inferior Vena Cava: A Murine Model of Deep Vein Thrombosis. *J Vis Exp*. 10.3791/56697 (130), (2017).